2024
Palliative Care and End-of-Life Care in Metastatic Pancreatic Cancer
O’Brien J, Halsey B, Connors M, Deng M, Handorf E, Berardi G, Lynch S, Sorice K, Reddy S, Meyer J, Bauman J, Dotan E. Palliative Care and End-of-Life Care in Metastatic Pancreatic Cancer. Journal Of Palliative Medicine 2024, 28: 217-223. PMID: 39636708, DOI: 10.1089/jpm.2024.0313.Peer-Reviewed Original ResearchEnd of lifeAggressive EOL carePalliative careDay of deathEOL carePC consultationIntegration of palliative careEnd of life careEnd-of-life careAssociated with worse qualityHealth care resourcesMetastatic pancreatic cancerQuality of lifePC teamAggressive careCare resourcesHospiceAverage length of timeTertiary cancer centerCareWorse qualityAverage timeCancer CenterBenefit patientsPancreatic cancerSystemic anti-cancer treatment and healthcare utilization at end of life: A SEER Medicare analysis.
Adelson K, Canavan M, Niu J, Zhao H, Nortje N, Xiang J, Giordano S, Cheng L. Systemic anti-cancer treatment and healthcare utilization at end of life: A SEER Medicare analysis. Journal Of Clinical Oncology 2024, 20: 276-276. DOI: 10.1200/op.2024.20.10_suppl.276.Peer-Reviewed Original ResearchEnd-of-lifeSystemic anticancer therapyDay of deathIntensive care unit useIntensive care unitHealthcare utilizationEmergency departmentCombined chemo-immunotherapyEnd-of-life chemotherapy useAssociated with healthcare utilizationImmunotherapy useChemo-ImmunotherapyIncreased healthcare useEnd of lifeAdverse quality of lifeAssociated with higher EDCare unitQuality of lifeSystemic anti-cancer treatmentHospice useDay hospiceHospice enrollmentSEER-Medicare databaseUse of chemotherapyHealthcare useSystemic anti-cancer therapy and cost at end of life: A SEER Medicare analysis.
Adelson K, Cheng L, Huang Y, Niu J, Zhao H, Nortje N, Xiang J, Giordano S, Canavan M. Systemic anti-cancer therapy and cost at end of life: A SEER Medicare analysis. Journal Of Clinical Oncology 2024, 42: 11092-11092. DOI: 10.1200/jco.2024.42.16_suppl.11092.Peer-Reviewed Original ResearchSystemic anticancer therapyCombined chemo-immunotherapyLiquid tumorsSolid tumorsDay of deathEmergency departmentRates of systemic therapySystemic anti-cancer therapySEER-Medicare databaseAnti-cancer therapyChemo-ImmunotherapyLT patientsSystemic therapyCI patientsSEER-MedicareST patientsIdentified patientsCost of drugsAssociated with higher costsEnd of lifeAnticancer therapyImmunotherapyChemotherapyPatientsTherapy
2023
End-of-Life Systemic Oncologic Treatment in the Immunotherapy Era: The Role of Race, Insurance, and Practice Setting
Canavan M, Wang X, Ascha M, Miksad R, Showalter T, Calip G, Gross C, Adelson K. End-of-Life Systemic Oncologic Treatment in the Immunotherapy Era: The Role of Race, Insurance, and Practice Setting. Journal Of Clinical Oncology 2023, 41: 4729-4738. PMID: 37339389, PMCID: PMC10602547, DOI: 10.1200/jco.22.02180.Peer-Reviewed Original ResearchConceptsSystemic treatmentEnd of lifeWhite patientsBlack patientsOdds ratioLarge real-world populationPractice settingsTreatment ratesPatient-level factorsEmergency department useIntensive care unitReal-world populationDay of deathImmunotherapy eraSystemic therapyOncologic treatmentCare unitDeidentified databaseDepartment usePatient raceInsurance typeMetastatic cancerDownstream careMedicaid patientsHigher oddsThe association between systemic anticancer therapy (SACT) at the end of life (EOL) and acute care use among patients treated at oncology practices participating in the Oncology Care Model (OCM).
Canavan M, Sheth K, Scott J, Westvold S, Adelson K. The association between systemic anticancer therapy (SACT) at the end of life (EOL) and acute care use among patients treated at oncology practices participating in the Oncology Care Model (OCM). Journal Of Clinical Oncology 2023, 41: 6580-6580. DOI: 10.1200/jco.2023.41.16_suppl.6580.Peer-Reviewed Original ResearchSystemic anticancer therapyDay of deathOncology Care ModelEnd of lifeAcute care useIntensive care unitInpatient admissionsED visitsCare useReceipt of chemotherapyAcute care utilizationEmergency department useProportion of decedentsRates of chemotherapyChi-square testICU stayIO therapyCare unitCare utilizationInpatient stayCT patientsDepartment useHospice useCare metricsOncology practiceThe impact of receipt of systemic anticancer therapy (SACT) near the end of life (EOL) on cost among oncology practices participating in CMS' Oncology Care Model (OCM).
Adelson K, Canavan M, Sheth K, Scott J, Westvold S. The impact of receipt of systemic anticancer therapy (SACT) near the end of life (EOL) on cost among oncology practices participating in CMS' Oncology Care Model (OCM). Journal Of Clinical Oncology 2023, 41: e18923-e18923. DOI: 10.1200/jco.2023.41.16_suppl.e18923.Peer-Reviewed Original ResearchSystemic anticancer therapyDay of deathOncology Care ModelEnd of lifeAcute care useSystemic therapyCT patientsCare useImpact of receiptMean episode costReceipt of chemotherapyReceipt of immunotherapyICU useED costsIO patientsPharmacy costsOncology practiceEpisode costsTreatment decisionsDownstream careCare modelAmbulatory settingPart BPatientsImmunotherapy
2022
Association between Short-Term Exposure to Air Pollution and COVID-19 Mortality: A Population-Based Case-Crossover Study Using Individual-Level Mortality Registry Confirmed by Medical Examiners
Kim H, Samet J, Bell M. Association between Short-Term Exposure to Air Pollution and COVID-19 Mortality: A Population-Based Case-Crossover Study Using Individual-Level Mortality Registry Confirmed by Medical Examiners. Environmental Health Perspectives 2022, 130: 117006. PMID: 36367781, PMCID: PMC9651183, DOI: 10.1289/ehp10836.Peer-Reviewed Original ResearchConceptsCOVID-19 mortalityShort-term exposureCOVID-19Cook County Medical Examiner's OfficeTime-stratified case-crossover designCounty Medical Examiner's OfficeRisk of mortalityCase-crossover studyInterquartile range increaseLocation of deathCase-crossover analysisCase-crossover designDay of deathIndications of modificationMedical Examiner's OfficeAmbient air pollutionCOVID-19 deathsRace/ethnicityComorbid conditionsMortality registryPotential confoundersMortality burdenIQR increaseEpidemiological studiesMortality
2021
Implementation of Inpatient Palliative Care Consultation Triggers and Its Impact on Healthcare Use in Patients with Relapsed/Refractory Acute Myeloid Leukemia
Xiang J, Prsic E, Adelson K, Prebet T. Implementation of Inpatient Palliative Care Consultation Triggers and Its Impact on Healthcare Use in Patients with Relapsed/Refractory Acute Myeloid Leukemia. Blood 2021, 138: 3018. DOI: 10.1182/blood-2021-149300.Peer-Reviewed Original ResearchRefractory acute myeloid leukemiaAcute myeloid leukemiaPost-intervention groupLength of stayAdvanced acute myeloid leukemiaPalliative care consultHigh symptom burdenLines of therapyCare consultEnd of lifeDay of deathSame admissionCare escalationSymptom burdenHospice enrollmentHealthcare utilizationSymptom managementPrimary teamMyeloid leukemiaEastern Cooperative Oncology Group performance statusRelapsed/Refractory Acute Myeloid LeukemiaHigh-risk hematology patientsAdvance care planning documentationPalliative care remainsPalliative care useTrends in end-of- life (EOL) systemic oncologic treatment in contemporary clinical practice: Insights from real-world data.
Canavan M, Wang X, Ascha M, Miksad R, Showalter T, Calip G, Gross C, Adelson K. Trends in end-of- life (EOL) systemic oncologic treatment in contemporary clinical practice: Insights from real-world data. Journal Of Clinical Oncology 2021, 39: 253-253. DOI: 10.1200/jco.2020.39.28_suppl.253.Peer-Reviewed Original ResearchDay of deathReal-world practiceTraditional chemotherapyCancer treatmentStudy periodPractice-level factorsOverall healthcare utilizationSystemic cancer treatmentRates of chemotherapyDays of lifeDe-identified databaseContemporary clinical practiceLogistic regression modelsElectronic health recordsCancer care organizationsSystemic therapySystemic treatmentOncologic treatmentHealthcare utilizationImmune therapyTargeted therapyStratified analysisHigher total costsLife careOncolytic therapyA validated model for prediction of survival to 6 months in patients with trisomy 13 and 18
Kosiv KA, Long J, Lee HC, Collins RT. A validated model for prediction of survival to 6 months in patients with trisomy 13 and 18. American Journal Of Medical Genetics Part A 2021, 185: 806-813. PMID: 33403783, DOI: 10.1002/ajmg.a.62044.Peer-Reviewed Original ResearchConceptsCongenital heart surgeryC-statisticMonths of ageTrisomy 13Heart surgeryCalifornia Perinatal Quality Care CollaborativePediatric Health Information System databaseHealth Information System databaseStatewide Health PlanningModel c-statisticCongenital heart diseasePrediction of survivalDay of deathParenteral nutritionCardiac surgeryMechanical ventilationStudy cohortValidation cohortCare CollaborativeHeart diseaseInformation System databaseInpatient dataCalifornia OfficeHealth planningSurgery
2019
Billed Palliative Care Services and End-of-Life Care in Patients with Hematologic Malignancies
Rao V, Belanger E, Egan P, LeBlanc T, Olszewski A. Billed Palliative Care Services and End-of-Life Care in Patients with Hematologic Malignancies. Blood 2019, 134: 384. DOI: 10.1182/blood-2019-121955.Peer-Reviewed Original ResearchPalliative care servicesDays of lifeEarly palliative careEnd of lifeHematologic malignanciesPalliative careMedicare beneficiariesCare servicesComorbidity indexSolid tumorsAdvisory CommitteeEOL quality measuresPoor performance statusReceipt of chemotherapyPalliative care specialistsHigher comorbidity indexIntensive care unitRetrospective claims dataService Medicare beneficiariesAmerican Cancer SocietyCare quality metricsMedicare spendingDay of deathNon-terminal patientsYear of deathTrends in checkpoint inhibitor therapy for advanced urothelial cell carcinoma (aUC) at the end of life: Insights from real-world practice.
Parikh R, Galsky M, Gyawali B, Riaz F, Kaufmann T, Cohen A, Adamson B, Gross C, Meropol N, Mamtani R. Trends in checkpoint inhibitor therapy for advanced urothelial cell carcinoma (aUC) at the end of life: Insights from real-world practice. Journal Of Clinical Oncology 2019, 37: 395-395. DOI: 10.1200/jco.2019.37.7_suppl.395.Peer-Reviewed Original ResearchAdvanced urothelial cell carcinomaPoor performance statusEnd of lifeSystemic therapyDay of deathQuarterly proportionPoor PSStudy periodFlatiron Health databaseSystemic therapy initiationCheckpoint inhibitor therapyFavorable toxicity profileUrothelial cell carcinomaDays of lifeSecular trend analysisChemotherapy initiationChemotherapy useCPI useReal-world practiceTherapy initiationInhibitor therapyPerformance statusPS 0Cell carcinomaNational guidelines
2018
Simple interventions to decrease use of chemotherapy in patients at the end of life.
Chiang A, Adelson K, Kapo J, Severino K, Lilenbaum R. Simple interventions to decrease use of chemotherapy in patients at the end of life. Journal Of Clinical Oncology 2018, 36: 181-181. DOI: 10.1200/jco.2018.36.30_suppl.181.Peer-Reviewed Original ResearchDays of lifeCourse of illnessEnd of lifeDay of deathGOC conversationsPrimary oncologistCare centerEarly palliative care referralPalliative care referralUse of chemotherapyPalliative care trainingChemotherapy utilizationCare referralPoor prognosisGOC discussionsCancer patientsUnnecessary treatmentGeneral oncologistsCare conversationsPost interventionPatientsChemotherapyMultidisciplinary teamPatient carePhysicians' skillsReasons for parental withdrawal of care in a pediatric intensive care unit in China
Ho K, Wang X, Chen L. Reasons for parental withdrawal of care in a pediatric intensive care unit in China. PLOS ONE 2018, 13: e0199419. PMID: 30044777, PMCID: PMC6059386, DOI: 10.1371/journal.pone.0199419.Peer-Reviewed Original ResearchConceptsPediatric intensive care unitIntensive care unitClinical improvementCare unitDisease severityNon-withdrawal groupMean hospital chargesDay of deathICU stayHospital stayHospital chargesWithdrawal groupMedical costsMedical carePatientsCareSubstantial proportionAdmissionStaySubstantial numberSeverityLower disease severityFinancial hardshipLarge proportionDays
2017
Primary care physician continuity and end-of-life care intensity among Medicare cancer decedents.
Wang S, Cramer L, Pollack C, Gross C. Primary care physician continuity and end-of-life care intensity among Medicare cancer decedents. Journal Of Clinical Oncology 2017, 35: 38-38. DOI: 10.1200/jco.2017.35.5_suppl.38.Peer-Reviewed Original ResearchDay of deathLife care intensityCancer diagnosisCancer decedentsCare continuityCare indexCare intensityLife careEnd Results-Medicare databaseIntensive care unit admissionPrimary care physician continuityPrimary care physician's careIntensity of endLife care patternsCare unit admissionOutpatient clinic visitsEmergency department visitsMonths of diagnosisLife care qualityPCP visitsPhysician continuityUnit admissionHospital deathICU admissionClinic visits
2016
Preparing for Value-Based Payment: A Stepwise Approach for Cancer Centers
Adelson KB, Velji S, Patel K, Chaudhry B, Lyons C, Lilenbaum R. Preparing for Value-Based Payment: A Stepwise Approach for Cancer Centers. JCO Oncology Practice 2016, 12: e924-e932. PMID: 27858564, DOI: 10.1200/jop.2016.014605.Peer-Reviewed Original ResearchConceptsSmilow Cancer HospitalEmergency departmentCancer HospitalCancer CenterValue-based paymentMost cancer centersYale-New HavenMedicare Limited Data SetIntensive care unitPatterns of careSite of careUrgent care servicesDay of deathBetter value careStepwise approachED utilizationHospital admissionCare unitUrgent careCare managementCare servicesPatient careHealth system leadershipValue careFutile treatmentAssociations Between End-of-Life Cancer Care Patterns and Medicare Expenditures.
Wang SY, Hall J, Pollack CE, Adelson K, Davidoff AJ, Long JB, Gross CP. Associations Between End-of-Life Cancer Care Patterns and Medicare Expenditures. Journal Of The National Comprehensive Cancer Network 2016, 14: 1001-8. PMID: 27496116, PMCID: PMC5577560, DOI: 10.6004/jnccn.2016.0107.Peer-Reviewed Original ResearchConceptsDay of deathLife care expendituresLife careIntensive endCancer decedentsIntensive care unit admissionCare expendituresLife care interventionsCare unit admissionEmergency department visitsSEER-Medicare databaseLast monthProportion of decedentsHospital referral regionsExpenditure differencesHospital deathICU admissionUnit admissionDepartment visitsHospice enrollmentIntensive careHighest quintileLater chemotherapyHospice useLowest quintileTrends in end-of-life cancer care in the Medicare program
Wang SY, Hall J, Pollack CE, Adelson K, Bradley EH, Long JB, Gross CP. Trends in end-of-life cancer care in the Medicare program. Journal Of Geriatric Oncology 2016, 7: 116-125. PMID: 26783015, PMCID: PMC5577563, DOI: 10.1016/j.jgo.2015.11.007.Peer-Reviewed Original ResearchConceptsLife cancer careDay of deathAggressive endLife careCancer careHospital deathHospice enrollmentEmergency departmentIntensive care unit admissionEnd Results-Medicare dataAggressiveness of endLate hospice enrollmentLife chemotherapy useCare unit admissionHospital referral regionsResult of cancerProportion of beneficiariesChemotherapy useICU admissionUnit admissionED visitsPatient demographicsTumor characteristicsReferral regionsMedicare beneficiaries
2014
Characterization of aggressive interventions within 30 days of death in lung cancer patients at Smilow Cancer Hospital (SCH).
Zhang B, Adelson K, Velji S, Rimar J, Longley P, Keane B, Chiang A, Lilenbaum R. Characterization of aggressive interventions within 30 days of death in lung cancer patients at Smilow Cancer Hospital (SCH). Journal Of Clinical Oncology 2014, 32: 20-20. DOI: 10.1200/jco.2014.32.30_suppl.20.Peer-Reviewed Original ResearchSmilow Cancer HospitalLung cancer patientsAggressive interventionRothman IndexDay of deathCancer patientsAdvanced cancerClinical conditionsAdvanced lung cancer patientsAdvanced lung cancerPalliative care consultationRetrospective chart reviewPatient's clinical conditionICU stayIOM guidelinesAggressive careChart reviewCancer HospitalCare consultationsCancer populationLung cancerFiscal year 2012Study populationEMR toolStage III
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply